UNSPSC 51362003: Flurazepam

This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IHP475989U, chemically known as 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2(3h)-one but generally known as flurazepam, which bears US NIH Compound Identifier 3393. European Medicines Agency schedules Flurazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07744MIG.

UNSPSC 51362003 Flurazepam is a Commodity code that captures individual pharmaceutical products procured by state and local health agencies, though recent solicitations tagged under this code show minimal direct demand for flurazepam itself and instead reflect broader state and local purchasing activity in pharmaceuticals, naloxone, and prescription-management systems. State and local governments under this code are acquiring controlled substances, emergency medications, and over-the-counter pharmaceutical products to support community health programs, emergency response capabilities, and pharmacy benefit administration. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across multiple state and local participants. Seminole County, Florida, for example, procures naloxone and drug deactivation systems to support community health initiatives, while the Texas Health and Human Services Commission is conducting exploratory market research into direct-to-manufacturer prescription programs to optimize cost and fulfillment efficiency for state pharmacy benefits.

Recent activity spans Florida, Texas, and Minnesota through a cooperative purchasing vehicle. Seminole County issued an IFB (Solicitation IFB60459723LAS) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023, requiring electronic submission through the county's e-Procurement Portal and compliance with drug-free workplace and E-Verify requirements. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (Solicitation S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota, Oregon, and other participating jurisdictions through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with awards effective July 1, 2026.